Does nebivolol improve endothelial dysfunction and will it rescue the reputation of the beta-blockers in the future?

References (11)

1. Oğuz A, Uzunlulu M, Yorulmaz E, Yalçın Y, Hekim N, Fici F. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus. Anadolu Kardiyol Derg 2007; 7: 383-7
2. Çengel A, Şahinarslan A. Nitric oxide and cardiovascular system. Anadolu Kardiyol Derg 2006; 6: 364-8
3. Szuba A, Podgórski M. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor - evidence from epidemiological and prospective clinical trials. Pharmacol Rep 2006; 58 Suppl:16-20 4. Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol 2007; 11: 115-21
4. Xiong Y, Fu YF, Fu SH, Zhou HH. Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocininduced diabetes. J Cardiovasc Pharmacol 2003; 42: 191-6
5. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-6
6. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-92
7. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24: 1023-30
8. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298: 1152-7
9. Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol 1988; 11: 552-63
10. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-71
11. Julius S, Gudbrandsson T, Jamerson K, Tariq Shahab S, Andersson O. The hemodynamic link between ins